Pharmacokinetic and pharmacodynamic effects of two omeprazole formulations on stomach pH and gastric ulcer scores

Summary Reasons for performing the study Limited data are available on the relative pharmacokinetics and pharmacodynamics of different omeprazole formulations. Objectives To compare pharmacokinetic and pharmacodynamic effects of a novel omeprazole formulation against a currently registered product. Study design Masked 2 period, 2 treatment crossover. Methods Twelve clinically healthy horses were studied over two 6‐day treatment periods. Horses were randomly assigned to receive a novel omeprazole paste (Ulcershield: ULS) or a currently registered reference omeprazole product (OMO). Gastric pH was measured continuously for 10 h on the day prior to commencing treatment (Day –1) and after 6 days of oral treatment (Day 5) using in situ antimony pH probes within an indwelling nasogastric tube. Plasma pharmacokinetics were determined on Days 0 and 6. Results Treatment significantly (P